MedTrace Logo

Continuous Administration of Oral Contraceptive, Primary Dysmenorrhea

NCT00517556 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2017-04-28

Study results available
· View outcomes & findings →

Summary

The primary hypothesis is that continuous administration of an OCP (CCOCP regimen) will result in more pain relief than a traditional 21/7 administration in primary dysmenorrhea (PD) patients.

Conditions

  • Dysmenorrhea

Interventions

DRUG

CCOCP

(CCOCP) continuous treatment with Monophasic oral gestodene/ethinyl estradiol

DRUG

Traditional OCP

(traditional OCP) (21 active days/7 inactive days) treatment regimen

Sponsors & Collaborators

  • Milton S. Hershey Medical Center

    lead OTHER

Principal Investigators

  • Richard S Legro, M.D. · Penn State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2011-03-31
Completion
2011-04-30

Countries

  • Croatia

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00517556 on ClinicalTrials.gov